Koers Laboratorio Reig Jofre SA BME
Aandelen
ES0165359011
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- EUR | - |
10/05 | Laboratorio Reig Jofre, S.A. rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024 | CI |
13/03 | Transcript : Laboratorio Reig Jofre, S.A., 2023 Earnings Call, Mar 13, 2024 |
Omzet 2024 * | 349 mln. 373 mln. | Omzet 2025 * | 379 mln. 406 mln. | Marktkapitalisatie | 215 mln. 230 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 11 mln. 11,78 mln. | Nettowinst (verlies) 2025 * | 14 mln. 15 mln. | EV/omzet 2024 * | 0,73 x |
Nettoschuld 2024 * | 39,5 mln. 42,31 mln. | Nettoschuld 2025 * | 33,3 mln. 35,67 mln. | EV/omzet 2025 * | 0,66 x |
K/w-verhouding 2024 * |
19,5
x | K/w-verhouding 2025 * |
15,2
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 21,19% |
Recentste transcriptie over Laboratorio Reig Jofre SA
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 56 | 01-01-06 | |
Carmen Esclapés
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-03 |
Chief Operating Officer | 52 | 01-01-03 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 56 | 01-01-06 | |
Director/Board Member | - | 31-12-14 | |
Director/Board Member | - | 31-12-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+55,32% | 815 mld. | |
+44,05% | 641 mld. | |
-6,75% | 352 mld. | |
+13,56% | 314 mld. | |
+10,68% | 303 mld. | |
+16,57% | 242 mld. | |
+13,31% | 218 mld. | |
+8,48% | 168 mld. | |
-2,81% | 159 mld. |